Perhaps if the CDC and the NIH stop pushing experimental vaccines for a moment and actually examine the science around Ivermectin we can all go back to normal lives. This document is on Substack because they can’t get published anywhere else.
Currently, as of August 4, 2021, the totality of the evidence is as follows;
IN-VITRO (BASIC SCIENCE): ivermectin has been shown to inhibit the replication of many viruses, including West-Nile, Zika, Dengue, Influenza, and most recently SARS- CoV-2
IN-VIVO: ivermectin diminishes viral load and protects against organ damage in animal models of SARS-CoV-2 infection and has multiple, potent anti-inflammatory properties.
IN-SILICO: numerous computer modeling studies have found ivermectin to have one of the highest binding affinities to the SARS-CoV-2 spike protein.
PHARMACOLOGIC: unparalleled safety profile over decades, prior WHO guidelines report side effects that are “primarily minor and transient” and experts have found severe adverse events to be “unequivocally and exceedingly rare.” Further, the IC-50 against SARS-CoV2 in lung and adipose tissue easily achieved with standard dosing (Caly/Wagstaff personal communication).
CLINICAL OBSERVATIONS/EXPERIENCE: numerous cases series, most notably one published from the Dominican Republic where over 3,000 consecutive patients presented to the ER, were treated with ivermectin, and only 16 were hospitalized and only 1 died. Also, innumerable doctors from multiple countries around the world report observing consistent clinical responses in treated patients with few treatment failure
OBSERVATIONAL CONTROLLED TRIALS (OCT): As of August 8, 2021, the results from 31 OCT’s including over 6,800 patients find that ivermectin strongly reduces the risk of transmission when taken either pre-or post-exposure and that ivermectin reduces time to recovery, rates of hospitalization, and mortality, including the propensity-matched study of Rajter et al which was published in the major medical journal Chest.
META-ANALYSES OF RANDOMIZED CONTROLLED TRIALS (RCT): 27 RCT’s including over 3,400 patients have been completed. Meta-analyses find that ivermectin reduces time to viral clearance, hastens recovery, and reduces mortality.
EPIDEMIOLOGIC: ivermectin distribution campaigns in Peru led to far lower COVID-19 case-fatality rates in those regions with widespread use. Further, large “test and treat” programs conducted by increasing numbers of Health Ministries report up to 75% reductions in the need for hospitalization in Mexico City and massive reductions in mortality in the states of Misiones, Argentina and La Pampas, Argentina.
Summary of the Evidence for Ivermectin in COVID-19 – by FLCCC Alliance – The FLCCC Alliance Community (substack.com)